Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
269 studies found for:    Open Studies | "Urinary Bladder Neoplasms"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Urinary Bladder Neoplasms" (269 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy
Conditions: Bladder Cancer;   Bladder Carcinoma;   Transition Cell Cancer;   Muscle Invasive Bladder Carcinoma
Interventions: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy;   Drug: Cisplatin;   Drug: Gemcitabine;   Radiation: Intensity Modulated Radiation Therapy;   Behavioral: Quality of Life Questionnaires;   Genetic: Urine Collection for Molecular Analysis;   Genetic: Blood Collection for Molecular Analysis
2 Recruiting Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
Condition: Urinary Bladder Neoplasms
Interventions: Procedure: Irreversible electroporation (IRE);   Device: NanoKnife
3 Recruiting Adjuvant Radiation for High Risk Bladder Cancer
Conditions: Bladder Cancer;   Squamous Cell Carcinoma of the Bladder;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Intervention: Radiation: 3D conformal radiation therapy
4 Recruiting Confocal Microscopy Dual Band in the Management of Bladder Cancer
Condition: Urinary Bladder Neoplasm
Intervention: Device: Cellvizio dual band
5 Recruiting Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Conditions: Recurrent Bladder Carcinoma;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus;   Procedure: Therapeutic Conventional Surgery
6 Recruiting MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
Conditions: No Evidence of Disease;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IVA Bladder Cancer;   Stage IVB Bladder Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
7 Recruiting A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Conditions: Urinary Bladder Cancer;   Bladder Tumors;   Transitional Cell Carcinoma of the Bladder;   Malignant Melanoma;   Melanoma;   Skin Cancer;   Carcinoma, Non-Small-Cell Lung;   Lung Cancer
Interventions: Biological: NEO-PV-01;   Biological: Nivolumab;   Other: Adjuvant
8 Unknown  Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Other: questionnaire administration;   Procedure: quality-of-life assessment;   Procedure: robot-assisted laparoscopic surgery;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery
9 Recruiting uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
Condition: Urinary Bladder Neoplasms
Interventions: Drug: Injection of 68Ga-NOTA-AE105;   Drug: Injection of 18F-FDG;   Device: Positron Emission Tomography and CT;   Device: Positron Emission Tomography and MRI
10 Unknown  Quality of Life in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Procedure: quality-of-life assessment;   Procedure: questionnaire administration
11 Not yet recruiting TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
Condition: Urinary Bladder Neoplasms
Intervention: Procedure: Cryoablation
12 Unknown  Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: selenium;   Drug: vitamin E;   Procedure: biopsy;   Procedure: chemoprevention;   Procedure: cryopreservation;   Procedure: cytology specimen collection procedure;   Procedure: diagnostic procedure;   Procedure: gene expression analysis;   Procedure: immunohistochemistry staining method;   Procedure: laboratory biomarker analysis;   Procedure: medical chart review;   Procedure: mutation analysis;   Procedure: polymerase chain reaction;   Procedure: quality-of-life assessment;   Procedure: questionnaire administration;   Procedure: study of socioeconomic and demographic variables
13 Unknown  3 Tesla MRI in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Procedure: Specimen Ultra-High field MRI;   Drug: chemotherapy;   Procedure: Cystectomy and Lymphadenectomy
14 Unknown  Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
Condition: Bladder Cancer
Interventions: Procedure: medical chart review;   Procedure: questionnaire administration;   Procedure: study of socioeconomic and demographic variables
15 Recruiting Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)
Condition: Bladder Cancer
Interventions: Device: HoLERBT;   Device: cTURBT
16 Unknown  A Study for Treatment of Superficial Bladder Cancer Using OGX-427
Condition: Bladder Cancer
Intervention: Drug: OGX-427
17 Unknown  Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: selenium;   Drug: vitamin E;   Procedure: chemoprevention
18 Recruiting Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Conditions: Bladder Carcinoma;   Recurrent Bladder Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Procedure: Therapeutic Conventional Surgery
19 Unknown  Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
Condition: Bladder Cancer
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: sorafenib tosylate;   Other: imaging biomarker analysis;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Procedure: neoadjuvant therapy;   Radiation: fludeoxyglucose F 18
20 Recruiting MK-3475/BCG in High Risk Superficial Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Intravenous MK-3475/ Intravesical BCG

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years